Article

J&J Opens Doxil Rationing Program To New Patients

Johnson & Johnson (JNJ) will begin allowing new patients to enroll in a rationing program to receive the cancer drug Doxil because some of the limited, remaining supply has been freed up.

In a notice posted on the Doxil website Wednesday, J&J said it will reopen enrollment in the program starting Friday because some prior requests from doctors have changed and freed up supplies. Some doctors told J&J that Doxil supplies earmarked for patients already enrolled were no longer needed or they opted patients out of the program, the company said.

About 1,000 patients are now receiving Doxil--which treats ovarian and other cancers--through an allocation program that J&J created last year to address a product shortage.

Read the full story: http://hcp.lv/K6a9Bp

Source: Morningstar

Related Videos
John Michael O'Brien, PharmD, MPH
4 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
Richard J. Nowak, MD, MS, Yale School of Medicine
4 experts are featured in this series.
Naim Alkhouri, MD
Christine Funke, MD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo